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SUMMARY 
Enhanced blood vessel (BV) formation is thought to drive tumor growth through elevated 
nutrient delivery. However, this observation has overlooked potential roles for mural cells in 
directly affecting tumor growth independent of BV function. Here we provide clinical data 
correlating high percentages of mural-β3-integrin negative tumor BVs with increased tumor 
sizes but with no effect on BV numbers.  Mural-3-integrin loss also enhances tumor growth in 
implanted and autochthonous mouse tumor models with no detectable effects on BV numbers 
or function. At a molecular level, mural-cell β3-integrin loss enhances signalling via a FAK-p-
HGFR-p-Akt-p-p65 thus driving CXCL1, CCL2 and TIMP-1 production. In particular mural cell 
derived CCL2 stimulates tumor cell MEK1-ERK1/2-ROCK2-dependent signaling and enhances 
tumor cell survival and tumor growth. Overall, our data indicate that mural cells can control 
tumor growth via paracrine signals regulated by 3-integrin, providing a previously 




- High percentages of mural-β3-integrin negative tumor BVs associate with poor prognosis 
in human cancers 
- Mural-3-integrin loss enhances tumor growth in implanted and autochthonous mouse 
tumor models without affecting BV numbers. 
- Mural-β3-integrin loss upregulates FAK-p-HGFR-p-Akt-p-p65 driven CXCL1, CCL2 and 
TIMP-1 production. 
- Mural cell derived CCL2 activates MEK1-ERK1/2-ROCK2-dependent tumor cell survival 




Weak mural-β3-integrin expression associates strongly with poor  prognosis in multiple cancers. 
Depletion of mural-β3-integrin stimulates cytokine production via the upregulation of FAK-p-
HGFR-p-AKt-p-p65 signaling. Mural cell derived CCL2 activates tumor cell growth via MEK1-
ERK1/2-ROCK2 pathway. ‘Pericrine’ signalling, ie. Pericyte derived signals can directly 



























The precise mechanisms underlying the role of tumor stromal cells in cancer growth are still 
unclear. In solid cancers, blood vessels are essential for the delivery of nutrients and oxygen 
(Hanahan and Weinberg, 2011). The formation of new tumor blood vessels, tumor angiogenesis, 
involves the enhanced proliferation and migration of endothelial cells, development of a vessel 
basement membrane and subsequent recruitment of supporting mural cells including pericytes 
(Chung et al., 2010). These cellular processes are thought to require changes in cell adhesion. 
The cell adhesion receptor, integrin vβ3, is upregulated in nascent tumor blood vessels, in 
both endothelial cells and pericytes, suggesting a functional role for this integrin in tumor 
angiogenesis. Importantly, despite strong preclinical data and the fact that potent 3-integrin 
inhibitors are now under development, previous strategies to target 3-integrin as anti-
angiogenic and anti-cancer strategies have failed in clinical trials (Mason, 2015; Tucci et al., 
2014). This is most likely because a deeper understanding of the role of this integrin in tumor 
blood vessels and tumor biology is still required.  Although β3-integrin in endothelial cells has 
been studied extensively (Brooks et al., 1994a; Brooks et al., 1994b; Brooks et al., 1995; 
Reynolds et al., 2009; Reynolds et al., 2002; Steri et al., 2014; Stupp and Ruegg, 2007), its role 
in pericytes still remains unknown.  
 
Pericytes are generally recognised for being able to cross-talk with endothelial cells and 
regulate blood vessel leakage (Armulik et al., 2011; Raza et al., 2010; Stratman et al., 2009). 
However, the correlation of pericyte abundance in controlling cancer growth and progression is 
still unclear (Caspani et al., 2014; Cooke et al., 2012; Furuhashi et al., 2004; O'Keeffe et al., 
2008; Sinha et al., 2016). Indeed, the molecular mechanisms behind the regulation of tumor 
progression by pericytes are still largely unknown. Recent studies have revealed that tumor 
endothelial cells can produce angiocrine factors, endothelial-derived factors, that can regulate 
tumor growth and chemosensitivity (Acharyya et al., 2012; Brantley-Sieders et al., 2011; Cao 
et al., 2014; Cao et al., 2017; Ghajar et al., 2013; Ghiabi et al., 2014; Gilbert and Hemann, 2010; 
Lu et al., 2013; Pedrosa et al., 2015; Tavora et al., 2014; Wieland et al., 2017). For example, 
NF-B signaling and its control of endothelial cell-derived cytokine production has been 
implicated in cancer progression and chemosensitivity (Acharyya et al., 2012; Cao et al., 2014; 
Cao et al., 2017; Gilbert and Hemann, 2010; Tavora et al., 2014). Similar roles for paracrine 
signals derived from pericytes were hitherto not known.  
Our findings suggest a new concept whereby direct cross-talk between mural cells and tumor 




In human cancers high percentages of tumor blood vessels that are mural-β3-integrin 
negative correlate with increased tumor size and enhanced disease progression 
 
Here we show that mural cell-3-integrin was expressed only in a sub-set of blood vessels and 
that mural-3-integrin-negative blood vessels were evident. The range of percentages of blood 
vessels that were mural-β3-integrin negative across individual patient samples was wide in 
human cutaneous melanoma (mean value 41%), diffuse large B cell lymphoma (mean value 
49%) and ER+ breast cancer (mean value 57%) (Figure 1 A; Supplementary figure 1 A-D). 
A high percentage of mural-3-integrin negative blood vessels (ie when more than the mean 
number of tumor blood vessels are mural-3-integrin negative) correlated significantly with 
patients stratified into those with increased: (1) tumor burden in human cutaneous melanoma 
(identified by increased Breslow thickness); (2) tumor cell proliferation in human contaneous 
melanoma (Figure 1 B; Supplementary figure 1 E); (3) tumor size in human diffuse large B 
cell lymphoma and human ER+ breast cancer (Figure 1 B), but not with a change in blood 
vessel density (Figure 1 C). Importantly, a high proportion of mural-3-integrin negative blood 
vessels correlated with patients with: (1) elevated metastasis incidence (Figure 1 D); (2) 
increased disease progression stage (Figure 1 E); (3) elevated incidence of relapse (Figure 1 
F) and (4) advanced aggressive cancer phenotype (Figure 1 G) in primary human cutaneous 
melanoma, diffuse large B cell lymphoma, ER+ breast cancer and mesothelioma respectively. 
Together these clinical data indicate that a high percentage of blood vessels that are mural-3-
integrin negative correlate with enhanced tumor size and progression, with no apparent effect 
on blood vessel density.  
Generation and characterisation of pdgfrβcre+;β3fl/fl mice  
In order to elucidate the possible mechanisms by which pericyte-β3-integrin loss could regulate 
cancer growth and progression, we generated a mouse model of pdgfrβcre-driven-β3-integrin 
deficiency, where 3-integrin deficiency was confirmed in tumor pericytes. Mendelian ratios, 
male : female ratios and average mouse weights were all normal for mice born to 
pdgfrβcre-;3fl/fl x pdgfrβcre+;3fl/fl mice (Supplementary figure 2 A-D). Pdgfrβcre+;3fl/fl mice 
showed no apparent defects in non-tumor burdened tissues (Supplementary figure 2 E) with 
poor cre-activity in pericytes of unchallenged skin but good cre activity in tumour pericytes 
(Supplementary Figure 2 F) (Reynolds et al., 2017). Mural cell purity was established and cell 
survival was not affected by loss of 3-integrin (Supplementary figure 2 H). Loss of 3-integrin, 
but not 1 or 5 subunits, was evident only in pericytes isolated from pdgfrβcre+;3fl/fl mice 
(Supplementary figure 2 I). Pericyte specificity of deletion was supported by expression of 3-
integrin in endothelial cells and fibroblasts from pdgfrβcre+;3fl/fl mice (Supplementary figure 
2 J and K). These data indicate good specificity of 3-integrin deletion in tumor associated 
pericytes from pdgfrβcre+;3fl/fl mice in the systems tested.  
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Loss of pericyte-3-integrin enhances tumor growth in mice 
To examine the effect of pericyte-3-integrin loss on tumor growth, pdgfrβcre-;3fl/fl and 
pdgfrβcre+;3fl/fl mice were injected subcutaneously with syngeneic mouse melanoma B16F0 
and Lewis lung carcinoma (LLC) cells.   Immunofluorescence analysis confirmed reduced 3-
integrin expression in PDGFR-positive and SMA-positive tumor blood vessel pericytes only 
in pdgfrβcre+;3fl/fl mice (Figure 2 A; Supplementary figure 2 L). B16F0 tumor growth and 
tumor cell proliferation (Ki67) were enhanced significantly in pdgfrβcre+;3fl/fl mice (Figure 2 B; 
Supplementary figure 2 M). The increase in tumor growth was confirmed using LLC tumor 
cells in pdgfrβcre+;3fl/fl mice (Figure 2 C). In a second experimental setting, B16F10 or LLC 
cells were injected via the tail vein and lung tumor burden measured by microCT imaging. No 
differences in the number of CMTPX-labelled tumor cells homing (2 h post tail vein injection) or 
seeding (48 h post injections) were observed between the lungs of each genotype 
(Supplementary figure 2 N). However, at 16 days post inoculation enhanced tumor burden 
was observed in the lungs of pdgfrβcre+;3fl/fl mice (Figure 2 D and E). This correlated with an 
increase in the number and size of B16F10 and LLC lung nodules in pdgfrβcre+;3fl/fl mice 
(Figure 2 F and G). Orthotopic growth of syngeneic mammary E0771 tumour cells was also 
enhanced in pdgfrβcre+;3fl/fl mice (Figure 2 H). However, although no difference in the number 
of spontaneous lung metastases was observed, the size of E0771 lung metastases was 
significantly increased in pdgfrβcre+;3fl/fl mice (Supplementary figure 2 O).  Corroborating 
these results at 13 weeks of age spontaneous pancreatic tumor growth was significantly 
enhanced in RIPtag-2+;pdgfrβcre+;3fl/fl mice compared with RIPtag-2+;pdgfrβcre-;3fl/fl mice 
(Figure 2 I). Together these data indicate that loss of pericyte-3-integrin does not affect tumor 
cell homing or seeding at distant sites but is sufficient to enhance tumor growth at primary and 
secondary sites.  
 
Pericyte-3-integrin deletion does not cause detectable changes in tumor blood vessel 
numbers or function  
The effect of pericyte-3-integrin loss on vascular properties was next examined. Blood vessel 
density, detected by immunostaining for endomucin, was not significantly different in B16F0, 
B16F10, LLC or E0771 tumors in pdgfrβcre-;3fl/fl and pdgfrβcre+;3fl/fl mice or spontaneous 
pancreatic tumors in RIPtag-2+;pdgfrβcre+;3fl/fl and RIPtag-2+;pdgfrβcre-;3fl/fl (Figure 3 A 
and B; Supplementary figure 3 A - D). The percentage of blood vessels lacking mural cells 
were not significantly changed between genotypes (Figure 3 A and B; Supplementary figure 
3 E and G).  No differences between the percentage of tumor blood vessels perfused (Figure 
3 C; Supplementary Figure 3 F) and the percentage of tumor blood vessels with basement 
membrane collagen IV in pdgfrβcre-;3fl/fl or pdgfrβcre+;3fl/fl mice were detected (Figure 3 D; 
Supplementary figure 3 H). Blood vessel leakage, tumour hypoxia and blood flow, were also 
not changed between genotypes (Figure 3 E, F; Supplementary figure 3 I, J). Lastly, 
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unchallenged skin of pdgfrβcre-;3fl/fl and pdgfrβcre+;3fl/fl mice showed no difference in blood 
vessel density, pericyte coverage or vessel leakage (Supplementary figure 3 K) most likely 
because previous reports, and our own data, indicate that pdgfr-promoter activity is low in 
mural cells of normal quiescent vessels (see Supplementary figure 2 F) (Heldin, 2013; Pietras 
et al., 2002; Wang et al., 2010). Together, these data suggest that the enhanced tumor growth 
in pdgfrβcre+;3fl/fl mice is not associated with any apparent effect on tumor blood vessel 
number, maturation, perfusion or flow functions and led us to investigate whether a possible 
paracrine effect of 3-null pericytes on tumor cells could affect tumor growth directly.  
 
Deletion of mural cell-3-integrin increases tumor cell growth independent of effects on 
tumor blood vessels 
In order to test the paracrine effect of3-null mural cells on tumor growth we developed 
experiments where wild type C57BL/6 mice were co-injected with tumor cells and either WT or 
3-null pericytes and the resulting tumors analysed.  Subcutaneous co-injection of B16F0 with 
3-null pericytes (1:8) showed enhanced tumor growth compared with co-injection of WT 
pericytes with B16F0 cells (Figure 4 A; Supplementary figure 4 A). No differences in tumor 
blood vessel density or pericyte coverage were observed between these groups (Figure 4 B). 
In a second model, co-injection of B16F10 cells with 3-null pericytes via the tail vein of wildtype 
C57BL/6 mice increased the number of B16F10 lung nodules and relative nodule size above 
that of WT pericytes at both 1:4 and 1:8 ratios (Figure 4 C; Supplementary figure 4 B). Using 
CMTPX tagged pericytes the survival of WT and 3-null pericytes, after injection in C57BL/6 
mice, was not different in vivo (Figure 4 D) suggesting that changes in tumor burden were not 
affected by differential pericyte survival. Furthermore, blood vessel density and pericyte 
coverage of blood vessels were not altered (Figure 4 E; Supplementary figure 4 C). B16F0 
cell invasion was similar when B16F0 cells were incubated with conditioned media from WT or 
3-null pericytes, suggesting that tumor cell invasion is not affected by paracrine signals 
generated from 3-null pericytes (Figure 4 F). In a further model, although the number of 
spontaneous E0771 lung metastases were similar between groups, the size of metastases was 
elevated in mice which had been co-injected with 3-null pericytes (Figure 4 G; 
Supplementary figure 4 D). In vitro, conditioned medium from 3-null pericytes was able to 
significantly enhance tumor cell number indicating that a paracrine signal from pericytes that 
controlled malignant cell growth (Figure 4 H).  These data, together with the evidence that 
tumor cell homing and seeding in the lungs is not affected by loss of pericyte-3-integrin, 
suggested that tumor growth, either at primary or secondary sites, were enhanced by the loss 
of pericyte3-integrin, pointing towards a possible paracrine mechanism of pericyte-tumor cell 
cross-talk that is regulated by pericyte-3-integrin.  
 
Increased FAK-p-HGFR-p-Akt-NF-B signaling and subsequent chemokine production 
in 3-deficient pericytes enhances tumor cell ROCK2 signalling and tumor cell survival 
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Next, the molecular mechanisms underlying pericyte-3-integrin – tumor cell cross-talk were 
explored. Unbiased, proteomics analysis of WT and 3-null pericytes identified increased 
expression of multiple candidates in 3-null pericytes.  These included focal adhesion kinase 
(FAK) a major known regulator of integrin signalling (Guan, 2010) (Figure 5 A; Supplementary 
Figure 5 A).  Proteome-Profiler tyrosine kinase and receptor tyrosine kinase arrays identified 
that 3-null pericytes also had significantly elevated levels of p-HGFR, p-Akt (S473) and p-Akt 
(T308) when compared with WT pericytes (Figure 5 B). The enhancement of Akt signalling 
was further supported by the increased expression of phospho-Akt1 (S122) and phospho-Akt1 
(S129) in 3-null pericytes (Supplementary Figure 5A). Previous studies have shown that 
elevated HGFR phosphorylation can activate Akt activity (Usatyuk et al., 2014), which has 
previously been recognised to regulate angiocrine signalling from endothelial cells 
(Guerrouahen et al., 2014). At a molecular level, Akt activity is also known to regulate NF-B-
mediated signalling (Cheng et al., 2011; Dan et al., 2008).  Western blot analysis confirmed that 
in addition to increased pHGFR expression, phosphorylation of both Akt (at S473) and the NF-
kB subunit p65 (at S536) levels were elevated in 3-null pericytes (Figure 5 C).  The 
upregulation of activated p65 was confirmed by increased nuclear localisation of p-p65 in 3-
null pericytes (Supplementary figure 5 B). Pharmacological inhibition of 3-integrin using 
cilengitide (Mas-Moruno et al., 2010) in WT pericytes also enhanced the levels of phospho-
HGFR, -Akt and -p65 (Supplementary figure 5 C). Activation of p65 has been associated with 
the upregulation of cytokine production (Poulos et al., 2016; Tavora et al., 2014). Here, 3-null 
pericytes produced significantly elevated levels of cytokine-related factors including sICAM-1, 
IL-1ra, CXCL1, CCL2 and TIMP-1 when compared with WT pericytes (Figure 5 D). The clinical 
relevance for the enhanced levels of p-Akt and nuclear p65 were supported by the significant 
up-regulation of p-Akt (Figure 5 E; Supplementary figure 5 D and E) and nuclear p65 (Figure 
5 F) in the mural cells of human cancers where more than the mean percentage of blood 
vessels were mural-3-integrin negative.  
 
In intervention studies FAK-kinase inhibitor (PF573228) treatment, reduced the expression of 
pY397-FAK and also the levels of p-HGFR, p-Akt and p-p65 in 3-null pericytes (Figure 5 G).  
Secondly, treatment with the HGFR inhibitor, PHA-665752, reduced HGFR phosphorylation, p-
Akt and subsequent p-p65 levels in 3-null pericytes (Figure 5 H).  Thirdly, treatment with the 
Akt inhibitor, LY294002, reduced both p-Akt and p-p65 levels (Figure 5 I). Together these data 
demonstrate that the elevated p-HGFR levels observed in 3-null pericytes lead to an increase 
in Akt-phosphorylation and subsequent p65-phosphorylation.  
 
The functional relevance of the molecular changes in p-HGFR, p-Akt and p-p65 in 3-null 
pericytes were then evaluated. CRISPR-Cas9 gene editing of Akt in 3-null pericytes (3-
null;AktKO PC) resulted in a reduction in the phosphorylation and expression of total Akt as well 
as a reduction in p-HGFR but not total HGFR (Figure 6 A).  CRISPR-Cas9 ablation of HGFR 
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in 3-null pericytes (3-null;HGFRKO PC) showed a reduction in the expression total HGFR and 
p-HGFR as well as a reduction in p-Akt but not total Akt (Figure 6 A).  Together these data 
indicate cross-regulation of p-Akt and p-HGFR in 3-null pericytes.  Downstream of this Akt- or 
HGFR-deletion resulted in a reduction in downstream p-p65 (but not total p65), TIMP-1 and 
CCL2.  Furthermore, exposure of B16F0 cells to conditioned medium from 3-null;AktKO or 3-
null;HGFRKO pericytes resulted in significantly reduced tumor cell survival when compared to 
B16F0 cells exposed to conditioned medium from Cas9-control transfected3-null pericytes 
(3-null;Cas9) (Figure 6 B).  Although gene-edited pericytes showed similar cell survival levels 
as controls (Supplementary figure 6 A), co-injection of 3-null;AktKO pericytes with B16F0 
cells reduced the enhanced tumor growth observed in mice co-injected with B16F0 and 3-
null;Cas9 pericyte controls (Figure 6 C). Together these data indicate a functional role for 
pericyte Akt and HGFR in the enhanced tumor cell survival induced by the loss of pericyte3-
integrin.  
 
The functional consequence of inactivation of NF-B signaling in 3-null pericytes was next 
assessed in the rescue of pericyte cytokine production and tumor cell growth control. 3-null 
pericytes were transfected with the super-repressor, non-phosphorylatable mutant form of I-
B, I-BSR, which has been reported to repress the NF-B pathway (Pikarsky et al., 2004). 
3-null pericyte transfection with the I-BSR was sufficient to reduce p-p65 levels back to WT 
pericyte levels (Figure 6 D) and significantly reduce expression levels of CXCL1, CCL2 and 
TIMP-1 (Figure 6 E) indicating that NF-B signaling was involved in the regulation of these 
secreted factors. Furthermore, exposure of tumor cells to conditioned medium from I-BSR 
transfected 3-null pericytes reduced the enhanced survival of B16F0, B16F10 and LLC cells 
when compared with exposure to conditioned medium from mock-transfected 3-null pericytes 
(Figure 6 F). In vivo, subcutaneous co-injection of B16F10 cells with I-BSR transfected 3-
null pericytes into C57BL/6 mice significantly decreased the number of lung nodules and 
relative nodule size when compared with mice co-injected with B16F10 cells and mock-
transfected 3-null pericytes (Figure 6 G). No change in cell survival was observed between 
mock transfected or I-BSR transfected 3-null pericytes (Supplementary Figure 6 B) 
suggesting that altered cell survival was unlikely to be responsible for the altered tumor growth 
in Figure 6 G.  Together these data indicate that the functional role of NF-B signalling in 3-
null pericyte control of tumor growth.  
To test the functional relevance of the enhanced levels of 3-null pericyte-derived CXCL1, 
CCL2 and TIMP-1 on enhanced tumor cell survival and tumor growth, 3-null pericytes with 
CRISPR-Cas9 depletion of CXCL1, CCL2 or TIMP-1 (3-null;CXCL1KO, 3-null;CCL2KO and 
3-null;TIMP-1KO respectively) were generated and target protein depletion confirmed by 
western blotting (Figure 6 H). Similar to the effect of deletion of Akt and HGFR in 3-null 
pericytes, exposure of B16F0 cells to conditioned medium from3-null;CXCL1KO, 3-
 11 
null;CCL2KO and 3-null;TIMP-1KO pericytes reduced B16F0 cell survival significantly compared 
with enhanced survival induced by exposure to conditioned medium from 3-null;Cas9 
pericytes (Figure 6 I). This effect on enhancing tumor cell survival was corroborated in vivo 
where tumor growth was reduced when co-injecting B16F0 cells with either3-null;CXCL1KO,  
3-null;CCL2KO or  3-null;TIMP-1KO pericytes compared with co-injection of B16F0 cells with 
3-null;Cas9 pericytes (Figure 6 J). Together these data suggest that the depletion of these 
factors in 3-null pericytes is sufficient to reduce the enhanced tumor growth observed and 
implicates them functionally, downstream of NFB activity, as pericyte-derived paracrine 
signals that regulate tumor growth.  
 
Since the fold expression increase in 3-null pericyte cytokine expression was highest for CCL2 
(4-fold increase compared with WT pericytes, see figure 5D) and that I-BSR transfection of 
3-null cells reduced CCL2 expression the most (4-fold decrease compared with mock 
transfected pericytes in figure 6E) we examined whether tumor cell CCR2, the receptor for 
CCL2, is involved in the enhanced tumor cell survival phenotype. B16F0 cells were exposed to 
conditioned media from WT and  3-null pericytes and also treated with the CCR2i inhibitor or 
vehicle alone. Inhibition of CCR2 was sufficient to reduce the enhanced tumor cell survival 
observed after exposure to 3-null pericyte conditioned medium suggesting that CCR2 is 
involved in tumor cell survival after exposure to 3-null pericyte conditioned medium 
(Supplementary figure 6 C).  
 
Using phosphoproteomic analysis of malignant cells, the molecular mechanism underlying the 
enhanced tumor cell survival and growth after exposure to 3-null pericytes was examined. 
Kinase substrate enrichment analysis of phosphoproteomics data identified that the ROCK2 
signalling pathway was the most significantly enriched pathway in tumor cells exposed to 3-
null pericyte conditioned medium compared with tumor cells exposed to WT pericyte 
conditioned medium (Figure 7 A). Phosphorylation levels of a number of proteins involved in 
tumor cell survival and progression supporting the notion that paracrine signals from 3-null 
pericytes enhanced cell survival based signalling in tumor cells (Supplementary figure 6 D).  
 
Non-muscle Myosin II has contractile properties and is regulated by phosphorylation of its light 
and heavy chains (Vicente-Manzanares et al., 2009). Importantly, a key phospho-substrate for 
many of the kinases arising from phosphoproteomic analysis was Myosin Light Chain 2 (MLC2, 
MYL12b and MYL9). Myosin II-driven contractility relies on multiple kinases. Amongst them, 
previously published work has shown that Rho-kinase (ROCK) inactivates the myosin light 
chain 2 (MLC2) phosphatase, which leads to increased phosphorylation of MLC2 (p-MLC2) 
and activity of Myosin II (Ito et al., 2004). MLC2 is also directly phosphorylated by ROCK 
(Vicente-Manzanares et al., 2009). Importantly, tumors arising from C57BL/6 mice injected with 
B16F0 melanoma cells plus 3-null pericytes showed increased levels of p-MLC2 protein (a 
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direct substrate of ROCK) when compared with B16F0s co-injected with WT pericytes (Figure 
7 B). These data indicate that tumors with 3-null pericytes grow with higher levels of 
actomyosin contractility, a feature associated with faster tumor growth in vivo (Georgouli et al., 
2019). Given that previous reports demonstrated that MEK1 and MAPK cascade signalling 
pathways are downstream of CCL2/CCR2 stimulated signalling (Fang et al., 2012; Tang and 
Tsai, 2012), we examined whether loss of3-null-pericyte-derived CCL2 was responsible for 
the enhancement of MEK1 and ROCK2 signalling pathways in B16F0. Western blot analysis 
showed reduced levels of p-MEK1/2, pERK1/2 and p-MLC2 in B16F0 cells exposed to 
conditioned medium from 3-null;CCL2KO pericytes compared with B16F0 cells exposed to 3-
null;Cas9 pericyte conditioned medium (Figure 7 C). These data suggest that CCL2 was 
involved in enhanced MEK1 and ROCK2 activity in tumor cells. Additionally, B16F0 tumors co-
injected with 3-null;CCL2KO pericytes showed a decrease in p-MLC2 levels, further linking a 
role for CCL2 in enhanced ROCK2-Myosin II activation in vivo (Figure 7 D). 
 
To test the functional role of ROCK2 and MEK1 in enhancing tumor cell survival, tumor cells 
were treated with a MEK1 inhibitor (U0126) or ROCK inhibitor (GSK269962A) after exposure 
to 3-null pericytes. Reduced Myosin II or ERK1/2 activity were confirmed after treatment 
(Figure 7 E).  B16F0 cells pre-treated with the U0126 MEK1-inhibitor or the GSK269962A 
ROCK-inhibitor displayed reduced tumor cell survival after exposure to 3-null pericyte 
conditioned medium compared to WT-pericyte conditioned medium (Figure 7 F). shRNA  
knockdown of ROCK2 in B16F0 cells resulted in reduced Myosin II activity (Supplementary 
figure 6 E). Although B16F0;ROCK2KO cells did not have compromised growth in vitro 
(Supplementary figure 6 F), depletion of ROCK2 in B16F0 cells was sufficient to reduce tumor 
growth in pdgfrcre+:3fl/fl mice back to that observed in B16F0;ROCK2WT or B16F0;ROCK2KO 
tumor growth in pdgfrcre-:3fl/fl mice  (Figure 7 G). These data confirm that the enhanced 
B16F0 tumor growth observed in absence of pericyte 3-integrin is dependent on B16F0 
ROCK2 activity. The relationship between MEK1 and ROCK2 activation has been reported 
previously (Arozarena et al., 2011; Vial et al., 2003), Orgaz et al, 2019 Cancer Cell In Press. 
Together these results demonstrate a functional role for tumor cell MEK1 and ROCK2-Myosin 





Our data establish that mural cells, by losing 3-integrin expression, thus enhancing signalling 
via the FAK-HGFR-Akt-NF-B pathway and increasing CCL2 mediated paracrine signals can 
increase tumor burden via tumor cell enrichment of MEK1 and ROCK2 signalling pathways in 
the absence of affecting tumor blood vessel numbers or functionality. These results are not 
expected and call for consideration of the role of tumor pericytes in the direct control of tumor 
growth and progression.  
 
Previous work has established that pericytes play critical roles in blood brain barrier function, 
vascular development, the control of vessel contraction, blood flow and haemostasis (Armulik 
et al., 2011; Raza et al., 2010). Based on these accepted functions as essential blood vessel 
supporting cells, elimination of pericytes was considered to be a logical anti-angiogenic strategy 
to control cancer. Indeed, antagonists of platelet derived growth factor signalling were shown 
to eliminate tumor pericytes resulting in vascular disruption and effective tumor regression 
(Heldin, 2013). However, similar strategies also result in enhancing vessel leakage and hypoxia 
thereby elevating metastasis (Cooke et al., 2012; Keskin et al., 2015; Xian et al., 2006). Thus 
targeting pericytes and inducing vascular disruption is unlikely to be a long term effective 
method of cancer control. Indeed, more recent reports have suggested that cancer progression 
can be associated with either increased or reduced pericyte association with tumor blood 
vessels (Cooke et al., 2012; Furuhashi et al., 2004; O'Keeffe et al., 2008; Sennino et al., 2007; 
Sinha et al., 2016; Xing et al., 2015; Yonenaga et al., 2005). Together these apparently 
conflicting data suggest that vascular disruption, or even enhanced blood vessel leakage via 
the loss of pericytes, may not be an effective method to control cancer.  Indeed, they suggest 
that pericytes might control tumor growth through other mechanisms that have not been 
investigated carefully until now.    
 
Loss of pericyte adhesion properties are likely to affect their association and recruitment to 
endothelial cells of the blood vessel wall. Integrins are a family of cell adhesion molecules that 
control cell-extracellular matrix interactions. Pericytes are known to express a variety of 
integrins including both 1- and 3-integrin heterodimers and reduced pericyte 1-integrin 
activity and, 4- or 6-integrin levels have all been shown to affect blood vessel maturation 
processes (Garmy-Susini et al., 2005; Reynolds et al., 2017; You et al., 2014), however the role 
of 3-integrin in pericyte function was unknown.   
 
Our data demonstrate that loss of pericyte-β3-integrin is sufficient to enhance tumor growth in 
the absence of changes in blood vessel density, pericyte recruitment vessel perfusion or tumor 
hypoxia. Previous work has demonstrated that global deletion of β3-integrin is sufficient to 
enhance tumor angiogenesis and tumor growth (Reynolds et al., 2002) and that deletion of 
endothelial cell β3-integrin only transiently inhibits tumor angiogenesis in established tumors 
(Steri et al., 2014). This enhanced angiogenesis was proposed to be due to elevated VEGF-
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induced responses of 3-null endothelial cells because of the up-regulated VEGF-receptor 2 
expression on these cells (Reynolds et al., 2004; Reynolds et al., 2002). Our current study 
suggests that the mechanisms that control tumor growth in the pericyte-specific-3-integrin 
knockout mice are distinct from those in global or endothelial cell-specific knockouts since the 
enhanced tumor growth is not associated with elevated angiogenesis. Thus explaining how 
pericyte-3-integrin controls tumor growth was explored.  
 
Our data point towards a possible new role for mural cells in directly affecting tumor growth and 
that this is controlled by 3-integrin expression. This conclusion is supported by clinical 
evidence where we show that a high percentage of blood vessels that are mural-3-intgerin 
negative is significantly associated with increased tumor size and progression in four different 
human cancers, including cutaneous melanoma, mesothelioma, lymphoma and breast cancer, 
without affecting blood vessel density. 
  
Previous studies from other laboratories, and our own, have demonstrated that vascular 
endothelial cells can control tumor progression and chemosensitivity without affecting tumor 
angiogenesis per se via paracrine signals, namely angiocrine signals, that include cytokines 
and chemokines (Acharyya et al., 2012; Gilbert and Hemann, 2010; Tavora et al., 2014). These 
findings have indicated that vascular cells can regulate tumor growth in a way beyond their 
roles simply in vessel development and maintenance. Our mouse models show that loss of 
pericyte-3-integrin is sufficient to enhance tumor growth via paracrine signals independent of 
tumor blood vessel function or numbers. Indeed, loss or inhibition of pericyte-3-integrin 
expression significantly enhanced the FAK-p-HGFR-p-Akt-p-p65-CCL2 pathway. Interestingly, 
FAK and Akt are known regulators of cytokine production and angiocrine signalling (LaBarbera 
et al., 2015; Perkins, 2012; Tavora et al., 2014). Importantly, the clinical relevance of these 
findings was supported by elevated mural cell Akt- and p65-phosphorylation in human 
melanoma, lymphoma and breast cancer patients that had a high proportion of mural-3-
integrin negative blood vessels. Furthermore, the expression of CXCL1, CCL2 and TIMP-1 
were all confirmed to be regulated by NF-B activation, suggesting that these paracrine factors, 
controlled by NF-B, could be at least part of the explanation of how 3-null pericytes regulate 
tumor growth. Within tumor cells, inactivation of ROCK2 in B16F0 tumor cells rescued the 
paracrine effects of 3-null pericytes on tumor growth both in vitro and in vivo suggesting that 
inhibition of ROCK2 in cancers with low pericyte-3-integrin expression could be a novel way 
to control cancer growth and progression. Given that this increase in tumor cell survival was 
evident even in the absence of other cell types, suggests that the mural cell-derived factors can 
control tumor cell survival independent of blood flow or other cell types.  
 
Overall, our study indicates that mural cells are not simply vessel supporting cells but that, via 
3-integrin, can regulate tumor growth via mural-derived paracrine signals. Our data provide 
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proof-of-principle for a new role of mural cells, and shed light on a new mechanism of tumor 
growth control.  
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Detailed methods are provided in the online version of this paper and include the 
following: 
 
KEY RESOURCES TABLE 
See separate document 
 
CONTACT AND REAGENT RESOURCE SHARING 
Further information requests and reagents should be directed to and will be fulfilled by the 
Lead Contact, Kairbaan Hodivala-Dilke (k.hodivala-dilke@qmul.ac.uk) 
 
HUMAN SAMPLE COLLECTION AND PATIENT INFORMATION 
Human ER+ breast cancer samples were obtained from the Barts Cancer Institute Breast 
Cancer Now tissue Bank and were covered by Research Tissue Bank Ethics Approval (Ethnic 
code 15/EE/0192). Human melanoma, mesothelioma and diffuse large B-cell lymphoma 
(Ethnic code 05/Q0605/140) samples were obtained with signed informed consent from 
patients and ethical committee approval. 
 
Animal Models 
pdgfrcre mice were obtained from Professor Ralf Adams (Max Planck Institute for Molecular 
Biomedicine, Münster, Germany). 3fl/fl mice were generated by Professor Katherine 
Weilbaecher (Morgan et al., 2010). pdgfrcre-;3fl/fl and pdgfrcre+;3fl/fl mice were maintained 
on a pure C57 background for experiments. 3fl/fl mice were bred with RIPtag-2 mice provided 
by Professor Douglas Hanahan, generating both male and female mice were used. mTmG 
mice were obtained from Cancer Research UK.  mTmG mice were crossed with pdgfrcre+ 
mice to generate pdgfrcre-;mTmG and pdgfrcre+;mTmG mice for Cre-specificity analysis. 
Unchallenged adult skin from TdTom;pdgfrcre+ and TdTom;pdgfrcre- control mice, fixed in 
4% formalin, sucrose infiltrated, and snap frozen in OCT were used to assess pdgfr-driven cre 
activity in skin mural cells.  
 
METHOD DETAILS  
Human tissue sections 
Formalin fixed paraffin embedded tissue samples from human melanoma, diffuse large B-cell 
lymphoma, breast cancer and mesothelioma were sectioned, dewaxed, and antigen retrieval 
carried out in boiling 10 mM citrate buffer pH 6.0, 4 m sections were washed three times in 
PBS, blocked in 1% normal goat serum (NSG) 0.1% TritonX-100 (TX-100) for 1 h. Sections 
were double or triple immunostained for mouse monoclonal anti-alpha-smooth muscle actin 
Cy3-conjugated (Sigma-Aldrich-#C6198) and for either rabbit monoclonal anti-CD31 (Abcam-
#ab76533), rabbit monoclonal anti-phospho-Akt (ser 473) (Cell Signaling Technology-#3787), 
rabbit monoclonal anti-NF-B p65 (Cell Signaling Technology-#8242), rabbit monoclonal anti-
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3-integrin (Abcam-#ab75872) or rabbit polyclonal anti-CD61 (ThermoFisher Scientific-#PA5-
32890). Sections were then washed three times with PBS, incubated with Alexa® 488-/546-
conjugated anti-rabbit diluted 1:200 in 1% NGS 0.1% TX-100, washed three times and mounted 
with Prolong Gold Anti-Fade Mountant with DAPI (ThermoFisher Scientific-#P36931). For triple 
immunostaining, the tissue sections were further processed by using Tyramide SuperBoost™ 
Kit (Invitrogen-#B4093) combined with IHC (TSA-IHC). Different primary antibodies were 
sequentially applied, followed by horseradish peroxidase-conjugated secondary antibody 
incubation and tyramide signal amplification. The slides were microwave heat-treated after 
each TSA operation. 
For data analysis, the percentage of 3-integrin or p-Akt or p65 and -SMA-double-positive 
blood vessels was calculated as the number of 3-integrin or p-Akt or p65 and -SMA-double-
positive blood vessels over the total number of -SMA-positive blood vessels. Patient data are 
expressed as those with either less, or more, than 50% of blood vessels that are mural β3-
integrin negative. 
 
PCR genotyping  
The primers for the Cre PCR: forward primer: 5’-GCTGTAGACGTAGTAAGTATCG-3’; reverse 
primer: 5’-GCTGGAGTTTCAATACCGGAG-3’. The reaction generates a fragment of 
approximately 669 bp. The primers for the 3-floxed PCR: forward primer: 5'-
TTGTTGGAGGTGAGCGAGTC-3' and reverse primer: 5'-GCCCAGCGGATCTCCATCT-3'. 
The PCR reaction generates a 272 bp fragment for the 3-floxed allele and a 182 bp fragment 
for the wild-type allele. All the primers were purchased from ThermoFisher Scientific. For PCR 
reactions, the 25 l reactions contain 21 l MegaMix-Blue (MicroZone, Client life science), 100 
ng DNA, 1 l of 10 nM forward and reverse primers respectively. For Cre PCR, the PCR 
program was run as a simplified hot start PCR with initial denaturation at 95 °C for 5 min, 35 
cycles of 30 s at 95 °C, 1.5 min at 60 °C and 1 min at 72 °C, followed by a final extension for 5 
min at 72 °C. For 3-floxed PCR, the PCR program was run with initial denaturation at 95 °C 
for 2 min, 35 cycles of 30 s at 95 °C, 30 s at 56 °C and 30 s at 70 °C, followed by a final 
extension for 8 min at 72 °C. The thermocycler used were GeneAmp PCR systems 9700 
(Applied Biosystems). 20 l of the PCR products were separated by electrophoresis on a 1.8% 
agarose gel, stained with ethidium bromide (0.25 g/ml) and viewed by a gel image system 
(BioRad, Germany).  
 
Cell lines 
Lewis lung carcinoma (LLC), B16F0 (melanoma, derived from C57BL/6), B16F10 (melanoma, 
derived from C57BL/6), E0771 (breast cancer, derived from C57BL/6) (all from ATCC). LLC, 
B16F0 and B16F10 were cultured in DMEM supplemented with 10% fetal bovine serum (Gibco 
10500 (batch 07Q8041K) Pencillin and Streptomcyin. E0771 cells were grown in RPMI 
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supplemented with 10% fetal bovine serum (Gibco 10500 (batch 07Q8041K) Pencillin and 
Streptomcyin.  Cell lines were maintained in a 5% CO2 incubator at 37C. 
 
Mouse tumor models 
All in vivo experiments have been performed according to Arrive Guidelines. 12-14 week old 
pdgfrcre-;3fl/fl and pdgfrcre+;3fl/fl mice were given a subcutaneous injection of either 1 x 105 
Lewis lung carcinoma (LLC) or B16F0 (melanoma, derived from C57BL/6) into the flank for 
subcutaneous tumor growth. Tumor growth was measured by using callipers every two days. 
Tumor volume (V) was calculated: V= (Length x width2) x 0.52. After 20-26 days, animals were 
culled, tumors excised and either fixed in 4% formaldehyde in PBS overnight, or snap frozen in 
liquid nitrogen for subsequent immunohistochemical analysis. For experimental metastasis 
assays, 5 x 105 LLC or B16F10 melanoma cells were injected via the tail vein of pdgfrcre-;3fl/fl 
and pdgfrcre+;3fl/fl mice. Lung tumor burden was measured by a Nano SPECT/CT® In vivo 
preclinical imager (Bioscan) 3-4 times over 16 days according to the manufacturer’s instruction 
(Wong et al., 2015). For breast cancer orthotopic model, 1 x 105 E0771 cells were orthotopically 
injected into mammary fat pad of pdgfrcre-;3fl/fl and pdgfrcre+;3fl/fl mice. RIPtag-
2;pdgfrcre-;3fl/fl; and RIPtag-2;pdgfrcre+;3fl/fl; were culled at 13 weeks of age. At necropsy, 
pancreas with peri-pancreatic lymph nodes, were fixed in 4% formaldehyde in PBS or snap 
frozen for subsequent immunohistochemical analysis.  
 
For co-injection tumor growth assays, wild type C57BL/6 mice (Charles River) were 
intravenously co-injected with 1 x 105 B16F10 cells and either 4 x 105 WT or 3-null pericytes, 
or with 1 x 105 B16F10 cells and either 8 x 105 WT or 3-null pericytes. Three weeks post 
injection, the mice were sacrificed and the number of metastases in their lungs was counted. 
For breast cancer orthotopic model, 1 x 105 E0771 cells were co-injected with either 4 x 105 WT 
or 3-null pericytes into the mammary fat pad of wild type C57BL/6 mice. To perform metastasis 
analysis, the tumor bearing mice were harvested when their primary tumor sizes reached 600 
mm3, and their lungs were fixed for further metastasis analysis. 
 
For in vivo rescue experiment, 3-null pericytes were transfected using the Nucleofector® 
electroporation system (Lonza) with either the empty vector (mock control) or I-BSR (kindly 
provided by Professor Neil Perkins) for 48 h. Wild type C57BL/6 mice were intravenously 
coinjected with 1 x 105 B16F10 cells and either 4 x 105 mock transfected- or I-BSR 
transfected-3-null pericytes. Three weeks post injection, mice were sacrificed and the number 
of metastases in their lungs was quantified by counting the average of the number of 
metastases across entire lung H&E stained section area from three different levels of the lungs, 
with 10 m separation between each level. H&E stained sections from E0771 metastases and 
RIPTag-2 metastases were used to assess metastatic burden.  
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In vivo cell tracking 
B16F10 melanoma, WT or 3-null pericytes, previously labelled with CellTrackerTM Red 
CMTPX Dye (Molecular probes, Invitrogen, Life Science), were resuspended at 0.5 x 106 cells 
per 100 ul of PBS and injected via the tail vein into mice. At 2 or 48 h post inoculation, mice 
were sacrificed and lungs were fixed and processed as previously described (Batista et al., 
2014). Lungs were dissected, photographed using a Leica M16F fluorescence 
stereomicropscope, snap-frozen in OCT (Killik, Bio-Optica, IT) and 4 m cryosections were 
prepared for analysis. Total number of CMTPX positive tumor cells or pericytes were quantified 
by counting the average of the number of CMTPX positive cells across entire lung section area 
from three different levels of the lungs (with 10 m separation between each level), using a 
Zeiss Axioplan microscope (Zeiss).  
 
Immunofluorescence 
Mouse tissues were fixed in formalin for 24 hr and transferred to 70% ethanol. The tissues were 
then paraffin embedded, sectioned, dewaxed, and unmasked in boiling 10 mM citrate buffer pH 
6.0. 5 m sections were washed three times in PBS, blocked in 1% normal goat serum (NSG) 
0.1% TritonX-100 (TX-100) for 1 hr. Sections were double immunostained for mouse 
monoclonal anti-alpha-smooth muscle actin Cy3-conjugated (Sigma-Aldrich-C6198) and for 
either rat monoclonal anti-endomucin (Santa Cruz Biotechnology-#sc-65495) or rabbit 
monoclonal anti-3-integrin (Abcam-#ab75872). Sections were washed three times with PBS, 
incubated with Alexa® 488-/546-conjugated anti-rabbit or Alexa® 488-conjugated anti-rat 
secondary antibody (Invitrogen) diluted 1:200 in 1% NGS 0.1% TX-100, washed three times 
and mounted with Prolong Gold anti-Fade Mountant with DAPI. The percentage of -SMA-
positive blood vessels with 3-integrin expression was calculated as described previously. For 
collagen IV (rabbit polyclonal anti-collagen IV (Abcam-#ab6586))/endomucin (rat monoclonal 
anti-endomucin (Santa Cruz Biotechnology-#sc-65495)) and 3-integrin (rabbit polyclonal anti-
CD61 (ThermoFisher Scientific-#PA5-32890))/PDGFR (rabbit monoclonal anti-PDGFR (Cell 
Signaling Technology-#3169) double immunostaining experiments, mouse tumors were snap-
frozen, sectioned and fixed in ice-cold acetone for 10 min. 4 m sections were blocked for 45 
min with 1.0% bovine serum albumin (BSA) and 0.1% Tween 20 in PBS. Primary antibodies 
were incubated overnight at 4C followed by incubation with Alexa 546-conjugated secondary 
antibody for 1 h at RT (Invitrogen) diluted 1:200 in 1.0% bovine serum albumin (BSA) and 0.1% 
Tween 20 in PBS, washed three times and mounted with Prolong Gold anti-Fade Mountant with 
DAPI (ThermoFisher Scientific). TdTom;pdgfrcre- and TdTom;pdgfrcre+ mouse 
unchallenged skin tissues were obtained from Neil Henderson lab (University of Edinburgh).  
 
In vitro, cells were fixed with 4% formaldehyde in PBS for 10 min at RT. Rabbit monoclonal anti-
phospho-NF-B p65 (Ser 536) (Cell Signaling Technology-#3033) antibody was incubated 
overnight at 4C and washed three times with PBS followed by incubation with Alexa® 546-
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conjugated secondary antibody (Invitrogen) for 1 h at RT diluted 1:200 in 1.0% bovine serum 
albumin (BSA) and 0.1% Tween 20 in PBS, washed three times and mounted with Prolong 
Gold anti-Fade Mountant with DAPI (ThermoFisher Scientific).  
 
Blood vessel density and pericyte coverage 
The number of endomucin-positive blood vessels present across the entire area of each mid-
line tumor section from size and age-matched tumors or unchallenged skins was counted and 
divided by the area of the section to determine tumor blood vessel density.  
For pericyte coverage, the percentage of -SMA-positive, endomucin-positive blood vessels 
were counted. 
 
Vascular perfusion  
Vascular perfusion was visualized by injecting mice via the tail vein with PE-conjugated 20 g 
of rat monoclonal anti-PE-PECAM (BioLegend-#102408) 10 min prior to culling. Tumors were 
snap frozen, sectioned and stained for endomucin. The ratio (%) of double-positive blood 
vessels over endomucin-positive vessels provided an indication of blood vessel perfusion. 
 
Hypoxia quantification (Pimonidazole) and vessel leakage (Hoechst diffusion) 
Hypoxia and extravascular diffusion (vessel leakage) were tested by injecting mice with 
pimonidazole (Hypoxyprobe™-1 Kit) intraperitoneally 1 h prior to culling, and followed by 
intravenous injection of Hoechst dye (0.4 mg, Sigma-Aldrich) 1 min prior to culling and anti-PE-
PECAM as above. Tumors were snap frozen, sectioned and fixed in ice-cold acetone for 10 
min. 100 m thick frozen tumor sections were incubated overnight at 4 °C with a FITC-
conjugated mouse monoclonal anti-pimonidazole (Hydroxyprobe HPI Burlington-#MA01803), 
and then washed and mounted. Sections were analyzed using confocal microscopy (LSM710, 
Carl Zeiss). Confocal stacks of 100 m were taken at 0.5 m intervals (20x) on multiple fields 
using 488 nm laser to excite anti-pimonidazole, 543 nm laser to excite anti-PE-PECAM, and 
740 nm Mai-Tai fentosecond pulsing laser to excite Hoechst. For Hoechst diffusion 
quantification, the mean areas for PE-PECAM and Hoechst staining for each 100 m stack was 
calculated using ImageJ software. The Hoechst dye diffusion leakage area was calculated 
relative to PE-PECAM stained vessel area. For hypoxia quantification, the hypoxia index was 
calculated as the area of pimonidazole staining intensity across the area of tumor section.   
 
Blood vessel collagen IV assessment 
The percentage of endomucin-positive vessels with collagen IV expression was calculated as 
the number of collagen IV and endomucin-double positive blood vessels over the total number 
of endomucin-positive blood vessels. 
 
Phospho-MLC2 staining and digital analysis  
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Tumors were formalin-fixed and paraffin-embedded using standard protocols. 4 μm thick 
sections were incubated at 60 C  for 20 min and then subjected to antigen retrieval using citric 
acid based antigen unmasking solution (1:100; Vector Laboratories-#H-3300) at 110 C for 6 
min in a Decloaking ChamberTM NxGen (Biocare Medical). Samples were blocked with Dual 
Endogenous Enzyme-Blocking Reagent (Dako-#S2003) for 10 min and then were incubated 
with rabbit polyclonal anti-phospho-MLC2 (1:50; Cell Signaling Technology-#3671) for 40 min 
at RT, washed and then incubated with biotinylated goat anti-rabbit secondary antibody (1:200; 
Vector Laboratories-#BA-1000)  for 30 min at RT. Signal was then amplified using VECTASTAIN 
ABC HRP Elite kit (Vector Laboratories-#PK-6100;) for 20 min at RT and the reaction was 
developed using Vector® VIP Peroxidase (HRP) Substrate Kit (Vector Laboratories-#SK-4600) 
for 10 min at RT. Staining was counterstained with Hematoxylin. 
Sections from tumor xenograft experiments were imaged using NanoZoomer S210 slide 
scanner (Hamamatsu, Japan). Staining quantification was performed using QuPath v0.1.2 
(Bankhead et al., 2017). The entire whole-section images (WSI) were analysed performing 
positive cell detection, and three different thresholds were applied according to the intensity 
scores (0, 1, 2 and 3). Next, the software was trained by creating random trees classification 
algorithm combined with the intensity information, in order to differentiate tumor from stroma, 
necrosis and immune cells. Values used in the analysis correspond to the quantification of p-
MLC2 in the tumor margins. 
 
Ultrasound analysis of blood flow, volume and perfusion 
High-resolution ultrasound imaging of B16F0 tumors using the Vevo® 2100 system with a 
MS250 transducer was performed according to manufacturer instruction (Visualsonics). For 
blood flow, volume and perfusion measurement, contrast-enhanced ultrasound imaging was 
performed according to manufacturer instructions (Vevo® 2100 system). Briefly, B16F0 tumor 
bearing pdgfrcre-;3fl/fl and pdgfrcre+;3fl/fl mice were administered with 100 μl of bolus Vevo 
Micromarker suspension (VisualSonics) via tail vein using tail vein MicromarkerTM catheter. The 





Primary pericyte, endothelial cell and fibroblast isolation and culture 
Primary mouse endothelial cells, fibroblasts and pericytes were isolated from mouse brains and 
maintained as previously described (Reynolds et al., 2017). Briefly, pdgfrcre-;3fl/fl and 
pdgfrcre+;3fl/fl  mouse brains were minced, collagenase type I digested (Gibco-#17100017), 
strained through a 70 m cell strainer (BD Falcon) and the resulting cell suspension plated on 
flasks coated with a mixture of 0.1% gelatin (Sigma-Aldrich-#G9136), 10 g/ml fibronectin 
(Merck-Millipore-#FC010) and 30 g/ml rat tail collagen (Sigma-Aldrich). Endothelial cells were 
purified by a single negative (Rat monoclonal anti-mouse FCsort-RII/III; BD Biosciences-
#553141) and two positive cell sorts (Rat monoclonal anti-mouse ICAM-2; BD Biosciences-
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#553326), using DYNAL® sheep anti-rat IgG-conjugated magnetic beads (ThermoFisher 
Scientific-#11035). During preparation of primary endothelial cells, fibroblasts were isolated 
from the non-endothelial cell population that was generated during the first positive sorting. For 
all cell types, passaging occurred when cells reached 70% confluency. Cells were trypsinized, 
centrifuged, washed with PBS and re-plated on pre-coated flasks for endothelial cells and 
pericytes and non-coated flasks for fibroblasts. For culture conditions, fibroblasts were cultured 
in DMEM + 10% FCS to passage 4, endothelial cells in MLEC medium (Ham’s F-12, DMEM 
(low glucose), 10% FCS, heparin and endothelial mitogen (Generon)) to passage 4-5. Pericytes 
were cultured in pericyte medium including supplied pericyte growth supplement, FBS and 
pen/strep (ScienCell-#0010) to passage 10. 
 
Generation of CRISPR/Cas9-KO cells 
SgRNAs were designed using the CRISPOR algorithm (http://crispor.tefor.net). sgRNA 
sequences targeting TIMP-1 (Gene ID: 21857), CXCL1 (Gene ID: 14825), CCL2 (Gene ID: 
20296), Akt1 (Gene ID: 11651), and HGFR (Met) (Gene ID: 17295) (see table S1) were cloned 
into the pLenti-CRISPR–EGFP plasmid (Addgene-#75159) using BsmBI enzyme site. 5.0 105 
cells were centrifuged at 300 g for 5 min and re-suspended in 100 μl of R1 buffer (Invitrogen). 
CRISPR/Cas9-EGFP plasmid DNA (10 μg) were added into the WT and 3-null pericytes and 
loaded into a 100 μl Neon electroporation tip (Invitrogen). Electroporation was performed using 
1350 mV for 20 ms with 2 pulse program on the Neon Electroporator (ThermoFisher Scientific). 
After electroporation, cells were rescued in pre-warmed supplemented media in the 0.1% 
gelatin with collagen and fibronectin-coated plates. 48 h post transfection, cells were washed 
with phosphate-buffered saline (PBS) and harvested with 500 μl of FACS buffer (1% BSA and 
0.5 mM EDTA in PBS). A 488-nm diode laser was used for the detection of EGFP. In each 
sample, viable singlet cells were gated via forward-scatter (FSC) laser and side-scatter (SSC) 
and EGFP positive cells, regardless of expression levels, were sorted using a FACSAriaTM III 
flow cytometer (BD Biosciences) at the Chelsea Flow Cytometry and Light Microscopy Facility. 
 
Generation of B16F0;ROCK2KO cell lines 
ROCK2 knockdown in B16F0 melanoma cells was achieved using doxycycline inducible Tet-
pLKO-neo lentiviral shRNA constructs (Addgene-#21916). shRNA sequences for ROCK2 (5’-
GCATCTCTTGAAGAAACAAAT-3’) and non-targeting shControl (5’-
GCGCGATAGCGCTAATAATTT-3’) were designed using The RNAi Consortium collection 
(MISSION® shRNA, Sigma-Aldrich) and plasmids were generated by GenScript USA Inc. For 
lentivirus generation, 2 x 106 HEK293T cells on p100 dishes were transfected with lentiviral 
vector (5 μg) along with packaging vectors (pMDLg/pRRE (2.5 μg), pRSV-Rev (2.5 μg) and 
pMD2.G (2 μg) (Addgene)) using Optimem-I and Lipofectamine 2000 (ThermoFisher Scientific). 
Supernatants with lentiviruses were collected 48 h after transfection, spun down and filtered 
(0.45 μm). For lentiviral transduction, 2.5 x 105 melanoma cells were seeded in T25 flasks and 
infected with lentiviruses. Stable cells were selected with 500 μg/ml G418 (Sigma-Aldrich). 
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Gene knock-down was induced by the presence of doxycycline in the culture media (2 μg/ml) 
for in vitro experiments. 
FACS analysis 
For characterization of primary mouse brain pericytes, pericytes were washed with PBS and 
trypsinized at 37°C. The cell suspensions were washed in medium containing serum and 
centrifuged at 1, 200 rpm for 3 min. Cells were washed with cold FACS buffer (1% BSA/PBS) 
and fixed with 4% formaldehyde for 10 min at room temperature. Cells were washed with FACS 
buffer and the cell suspensions were incubated with the following primary antibodies: Rabbit 
polyclonal anti-NG2, Alexa Flour®488 conjugated (Merck Millipore-#AB5320A4), Rat 
monoclonal PE-anti-CD31 (BioLegend-#102508), rat monoclonal PE-anti-CD11b (Mac1) 
(BioLegend-#101208), rat monoclonal APC-anti-PDGFR (BioLegend-#136008), rat 
monoclonal APC-anti-PDGFR (BioLegend-#135908), rat monoclonal PE/Cy7-anti-CD146 
(BioLegend-#134714) for 30 min. Cells were then washed three times in sample buffer and re-
suspended in a final volume of 400 ml. As a control, unstained cells were FACS sorted.  
 
Proteome profiler phospho-receptor tyrosine kinase and tyrosine kinase arrays 
WT and 3-null pericytes were grown in normal pericyte media and the whole-cell lysates were 
extracted after 72 h incubation. Phospho-receptor tyrosine kinase and tyrosine kinase arrays 
(Proteome-Profilers ARY001B & ARY003B, R&D systems) were processed according to the 
manufacturer’s instruction using 300 g of lysates per membrane. Pixel analysis was used for 
quantification with Image J software.  
 
Western blotting  
Pericytes, endothelial cells or fibroblasts were harvested and lysed with NP40 lysis buffer 
(Invitrogen). Protein concentration was determined using the Bio-Rad Dc Protein Assay Kit 
(Bio-Rad Laboratories). 15-30 μg of protein from each sample was loaded onto 8-12% 
polyacrylamide gels. The protein was transferred to a nitrocellulose membrane and incubated 
for 1 h in 5% milk phosphate buffered saline with 0.1% Tween-20 (PBS-T), followed by an 
overnight incubation of primary antibody diluted 1:1000 in 2% milk PBS-T at 4°C. The blots 
were then washed three times with PBS-T and incubated with the relevant horseradish 
peroxidase (HRP)-conjugated antibody diluted 1:1000 in 2% milk in PBS-T, for 1h at RT. 
Chemiluminescence was detected by exposing the membrane to high performance Super XR 
film (Fujifilm, PYSER-SGI limited). Densitometry readings were calculated with ImageJ 
software. Hsc70 was used as loading control. The following antibodies were used: rat 
monoclonal anti-endomucin (Santa Cruz Biotechnology-sc-65495), rabbit monoclonal anti-3-
integrin (Cell Signaling Technology-#4702), rabbit monoclonal anti-5-integrin (Cell Signaling-
#3629), rabbit monoclonal anti-1-integrin (Cell Signaling Technology-#4706), rabbit 
monoclonal anti-PDGFR (Cell Signaling Technology-#3169), rabbit polyclonal anti-NG2 
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(Merck Millpore-AB5320), rabbit monoclonal anti-NF-B p65 (Cell Signaling Technology-#8242), 
rabbit monoclonal anti-phospho-NF-B p65 (Ser 536) (Cell Signaling Technology-#3033), 
rabbit monoclonal anti-Akt (Cell Signaling Technology-#4691), rabbit monoclonal anti-phospho-
Akt (Ser 473) (Cell Signaling Technology-#4060), mouse monoclonal anti-Hsc70 (Santa Cruz 
Biotechnology-#sc7298), goat polyclonal anti-MCP-1 (CCL2) (ThermoFisher Scientific-#PA5-
46954), rat monoclonal anti-CXCL1 (ThermoFisher Scientific-#MA5-23811), mouse 
monoclonal anti-TIMP-1 (ThermoFisher Scientific-#MA5-13688), rabbit monoclonal anti-
Myosin Light Chain 2 (Cell Signaling Technology-#3672), rabbit anti-phospho-FAK (Tyr397) 
(Cell Signaling Technology-#3283), mouse monoclonal anti-Met (HGFR) (Santa Cruz 
Biotechnology-#sc-8057), rabbit monoclonal anti-phospho-Met (HGFR) (Tyr1234/1235) (Cell 
Signaling Technology-#3077), mouse monoclonal anti-Akt1 (Cell Signaling Technology-#2967), 
rabbit polyclonal anti-phospho-MEK1/2 (Ser217/221) (Cell Signaling Technology-#9121), 
mouse monoclonal anti-Rock II (Biosciences-#610624). 
 
Mass spectrometry-based phosphoproteomics 
WT and β3-null pericytes were seeded in 100 cm2 Petri dishes at (1 x 106 cells/ml).  
concentration. B16f0 cells were treated with CM from WT and β3-null pericytes for 30 min and 
24 h in 100 cm2 Petri dishes (1 x 106 cells/ml). Cells were washed twice with cold PBS 
supplemented with 1 mM Na3VO4 and 1 mM NaF and lysed in 500 ul urea buffer (8 M urea in 
20 mM in HEPES pH 8.0 supplemented with 1 mM Na3VO4, 1 mM NaF, 1 mM Na4P2O7 and 1 
mM sodium β-glycerophosphate). Cell lysates were homogenized by sonication for 15 cycles 
of 30 s on 35 s off (Diagenode Bioruptor® Plus, Liege, Belgium). Insoluble material was 
removed by centrifugation at 16,000 x g for 15 min at 4 oC and protein in the cell extracts was 
quantified by bicinchoninic acid (BCA) analysis (ThermoFisher Scientific-#23225). 
For phosphoproteome analyses, we used published methods (Gruhler et al., 2005; Larsen et 
al., 2005; Montoya et al., 2011) . As they were eluted from the nano-LC system, peptides were 
infused into the online connected Q-Exactive Plus system operating with a 2.1 s duty cycle. 
Acquisition of full scan survey spectra (m/z 375-1,500) with a 70,000 FWHM resolution was 
followed by, data-dependent acquisition in which the 15 most intense ions were selected for 
HCD (higher energy collisional dissociation) and MS/MS scanning (200-2,000 m/z) with a 
resolution of 17,500 FWHM. A 30s dynamic exclusion period was enabled with an exclusion list 
with 10 ppm mass window. Overall duty cycle generated chromatographic peaks of 
approximately 30 s at the base, which allowed the construction of extracted ion chromatograms 
(XICs) with at least 10 data points. The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaino et al., 2016). Partner 
repository with the dataset identifier PXD014513 (project DOI 10.6019/ PXD014513) 
Mascot Daemon 2.5.0 was used to automate peptide identification from MS data. Peak list files 
(MGFs) from RAW data were generated with Mascot Distiller v2.6.1.0 and loaded into the 
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Mascot search engine (v2.5) in order to match MS/MS data to peptides (Perkins et al., 1999). 
The searches were performed against the SwissProt Database (SwissProt_2018_09. fasta) 
with a FDR of ~1% and the following parameters: 2 trypsin missed cleavages, mass tolerance 
of ±10 ppm for the MS scans and ±25 mmu for the MS/MS scans, carbamidomethyl of Cys as 
a fixed modification, PyroGlu on N-terminal Gln and oxidation of Met and phosphorylation on 
Ser, Thr, and Tyr as variable modifications. The in-house developed Pescal software was used 
for label-free peptide quantification (Cutillas, 2017; Wilkes et al., 2017), XICs for all the peptides 
identified across all samples were constructed with ±7 ppm and ±2 min mass and retention time 
windows, respectively. Peak areas from all XICs were calculated. Undetectable peptides were 
given an intensity value of 0. Values of 2 technical replicates per sample were averaged and 
intensity values for each peptide were normalized to total sample intensity. Unpaired, two-tail 
Student’s t test was used to assess significance in phosphoproteomics data. 
 
In vitro inhibitor experiments 
For v3-integrin inhibitor experiments, 3-null pericytes were treated with either placebo or 20 
M Cilengitide (purchased from Bachem) for 24 h. For HGFR inhibitor experiments, 3-null 
pericytes were treated with either DMSO or 1 M HGFR inhibitor (PHA-665752, provided by 
Dr. Stéphanie Kermorgant) for 10, 30 and 60 min respectively. For Akt inhibitor experiments, 
3-null pericytes were treated with either DMSO or 10 M Akt inhibitor (LY294002, Sigma-
Aldrich-#L9908) for 10, 30 and 60 minutes respectively. For FAK inhibitor experiments, 3-null 
pericytes were treated with either DMSO or 10 M FAK inhibitor (PF573228, TOCRIS-#3239) 
for 24 hours respectively.  
For MEK or ROCK inhibitor experiments,  B16F0 cells were treated with either the conditioned 
medium from WT or 3-null pericytes in the presence of either DMSO, MEK inhibitor (U0126, 
TOCRIS-#1144) or ROCK inhibitor (GSK269962A, TOCRIS-#4009) for 3 days in MTS 
experiments and 3 days for in vivo experiments or 1 day for western blot analysis.  
 
In vitro treatment of B16F0 cells with CCR2i  
CCR2i was discovered through structure-activity relationship modification of screening hits and 
synthesized by the Medicinal Chemistry Department at ChemoCentryx (Mountain View, CA) 
according to procedures described (Patent Application Numbers: WO 2014089495 and WO 
2016187393). B16F0 cells were treated with conditioned medium form 3-null pericytes in 
combination or not with CCR2i for 48 h for MTS assays. 
 
Cytokine arrays  
WT and 3-null pericytes or transfected WT and 3-null pericytes were grown in normal pericyte 
media. After 72 h of transfection, the whole-cell lysates were extracted. Mouse cytokine arrays 
(Proteome-Profiler ARY006, R&D systems) were processed according to the manufacturer’s 
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instruction using 300 g of lysates per membrane as previously described (Tavora et al., 2014). 
Pixel analysis was used for quantification with Image J software.  
 
Conditioned media production from WT/3-null pericytes, Cas9, AktKO, HGFRKO, 
CXCL1KO, CCL2KO, TIMP-1KO or mock/I-BSR transfected pericytes 
WT and 3-null pericytes were cultured with pericyte medium for 72 h. This medium was then 
collected and applied to B16F0, B16F10, LLC cells for 3 days at 37C and tumor cell survival 
was assessed using the MTS assay as described later. For mock/I-BSR-transfected pericyte 
medium, the pericytes were transfected using the Nucleofector® electroporation system (Lonza) 
with either the empty vector or I-BSR. After 72 h incubation, this medium was collected and 
applied to B16F0, B16F10, LLC cells for 3 days. 
 
In vitro cell viability assays 
LLC, B16F0 or B16F10 cell survival was assessed using the CellTiter 96® Aqueous One 
Solution Reagent (Promega-#G3582), according to the manufacturer’s instructions. Plates 
were read at a wavelength of 490 nm, with absorbance measured relative to blank wells 
containing reagent only.  
 
 
Transwell invasion assays 
Invasion assays were performed using transwell polycarbonate membranes (Sigma Aldrich). A 
suspension of 5 x 104 B16F0 cells in 100 l OptiMEM was seeded in the upper chamber of the 
transwell, being the 8 m-pore membrane pre-coated with 50 l of collagen (3 mg/ml in serum 
free DMEM). The lower chamber was filled with conditioned medium from WT or 3-null 
pericytes during 48 h. At the endpoint membranes were fixed with PFA 4% and stained with 
DAPI. Number of cells per field were quantified using using a Zeiss Axioplan microscope (Zeiss).  
 
B16F0;ROCK2KO in vivo tumor growth assays with doxycycline 
pdgfrcre-;3fl/fl and pdgfrcre+;3fl/f were injected with 1 x 105 B16F0;ROCK2KO cells or and 
B16F0;ROCK2WT cells. Induction of the transgene in the cell lines in vivo was performed by 
administering doxycycline 2 mg/l in drinking water with 5% sucrose. The administration of 
doxycycline took place once the tumors were palpable (7 days after injection).   
 
Animal ethical regulations 
All animal procedures were approved by our local animal ethics committee, Queen Mary 




LEAD CONTACT AND MATERIALS AVAILABILITY  
Further information and requests for resources and reagents should be directed to and will be 
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Figure 1. High percentages of tumor blood vessels that are mural-β3-integrin negative 
correlate with increased tumor size and enhanced disease progression in human 
cancers. (A) Human cutaneous melanoma (n=53), human diffuse large B-cell lymphoma 
(DLCBL) (n=54) and human breast cancer (n=80) sections double-immunostained for β3-
integrin and -SMA. Representative images of melanoma sections. Arrows, β3-integrin 
negative blood vessels. Bar charts, % of blood vessels that are mural 3-integrin negative for 
individual patients. (B) Violin plots, individual tumor size. (C) CD31 immunostaining and blood 
vessel density. (D) In cutaneous melanoma patients, more than the mean % (>41%) of tumor 
blood vessels that are mural-β3-integrin negative associated significantly with increased 
metastasis incidence (n=50 patient samples). (E) In human lymphoma, more than the mean 
(49%) percentage of muralβ3-integrin negative tumor blood vessels (tumor blood vessels that 
are mural-β3-integrin negative) stratified tumors with advanced disease (stages II-IV) (n=103 
patient samples). (F) Breast cancer patients with more than the mean % (57%) of tumor blood 
vessels that are mural-β3-integrin negative stratified into those with an increase in relapse 
incidence (n=63 tumor samples). (G) In human mesothelioma, a high percentage of mural-β3-
integrin negative blood vessels (>51% of tumor blood vessels that are mural-β3-integrin 
negative) significantly stratified those with advanced, aggressive types of mesothelioma 
including biphasic and sarcomatoid mesothelioma (n=22 patient samples). Each sample on the 
violin plots represent individual patient data. Means ± S.E.M are given. **p < 0.01, ***p < 0.001. 
N.S., no significant difference. Scale bar in (A) 25 m. (B, C, E, G) Student’s t test. (D, F) Chi-
square test.  
   
Figure 2, Pericyte-β3-integrin-deletion increases tumor growth. (A) Double 
immunofluorescence staining for 3-integrin in B16F0 subcutaneous tumours in 
pdgfrcre+;3fl/fl and pdgfrcre-;3fl/fl mice. (B) B16F0 and (C) LLC tumor growth in 
pdgfrcre+;3fl/fl and pdgfrcre-;3fl/fl mice (n=10-14 mice per group). Representative images of 
B16F0 and LLC tumors are given. (D, E) Pdgfrcre-;3fl/fl and pdgfrcre+;3fl/fl mice were 
injected with either B16F10 melanoma (D) or LLC cells (E) via the tail vein. Representative 
high-resolution microCT images of lung capacity 16 days post tumor cell inoculation are given. 
Red signal represents air in lungs. Graphs represent lung capacity and % loss of lung capacity 
(n=4-5 mice imaged per group). (F, G) Loss of pericyte β3-integrin expression significantly 
increased the number and size of lung nodules in both B16F10 (F) and LLC (G). Bar charts 
represent means ± s.e.m. (n=7-9 mice per group). Representative images of tumor burdened 
lungs and their hematoxylin and eosin (H&E)-stained sections are given. (H) Orthotopic E0771 
tumour growth. (n=6 mice/group). (I) Tumor size in 13 week old RIPtag-2;pdgfrcre+;3fl/fl and 
RIPtag-2;pdgfrcre-;3fl/fl mice (n=8-10 mice per group). H&E of pancreatic tumor sections 
provided.  *p < 0.05, **p < 0.01, ***p < 0.001. (B-E, H) Two-way ANOVA test. (F-G, I) Student’s 
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t test. Scale bars in (A) 10 m, (B-E) 5 mm, (F, G) gross lung, 1.0 cm, H&E sections, 500 m, 
(I) 200 m. 
 
Figure 3. Tumor blood vessel density, perfusion, pericyte coverage, leakage and blood 
flow are not affected by pericyte-3-integrin-loss. Midline sections of (A) B16F0 
subcutaneous tumors and (B) primary RIPtag-2 tumors immunostained for endomucin to detect  
blood vessels (n=4 mice/group) or double immunostained for endomucin and -SMA for % 
pericyte-free vessel analysis. (C) Mice injected antemortem via the tail vein with a PE-PECAM 
antibody (red) to detect perfused blood vessels. Tumor sections subsequently immunostained 
for endomucin to detect all blood vessels (green) and the % of perfused blood vessel assessed 
by counting the % of endomucin positive blood vessels that displayed PE-PECAM. (n=3-5 
tumors/group). (D) Tumour sections double immunostained for basement membrane marker 
collagen IV (green) and CD31 (red). Bar charts, percentage of blood vessels with associated 
collagen IV expression (n=9-10 B16F0 tumors/group) (n=4 RIPtag-2 tumors/group). (E) For 
blood vessel leakage mice were injected via the tail vein, in an antemortem process, with PE-
PECAM ab (red) and Hoechst dye (blue).   Relative area of Hoechst dye uptake into 
perivascular tumor cells to area of PE-PECAM provides an indication of vessel leakage. Bar 
charts, means ± s.e.m. (n=4-5 tumors analyzed per group). (F) Doppler ultrasonography in live 
mice provides relative blood flow, tumor perfusion, and tumor blood volume in subcutaneous 
B16F0 tumors. Representative ultrasound images. Bar charts, quantitation across the whole 
tumors (n=4–5 tumors analyzed per group). N.S., no significant difference. (A-F) Student’s t 
test. Scale bars in (A-C) 50 µm, (D) 10 µm, (E) 25 µm and (F) 5 mm.  
 
Figure 4. 3-integrin deficient pericytes enhance tumor cell growth independent of the 
tumor vasculature. (A) Tumour growth in WT mice injected subcutaneously with either B16F0 
cells plus WT pericytes, or B16F0 plus 3-null pericytes at 1:8 ratios. (n=10 tumors/group). (B) 
Blood vessel density and the percentage of vessels without associated -SMA positive pericyte 
coverage (n=10 tumors/group). (C) B16F10 tumor growth in lungs of wildtype mice injected via 
the tail vein with either B16F10 cells plus WT pericytes or B16F10 cells plus 3-null pericytes 
at 1:4 or 1:8 ratios at 21 days post injection. Gross tumor burdened lungs and H&E stained 
images are given (n=3-5 mice/group). (D) WT mice injected with either 0.5 x 106 CMTPX 
labelled WT pericytes or 3-null pericytes and lungs harvested at 2 h and 48 h after the injection. 
Representative stereomicroscopic images of fresh lungs from both genotypes (n=4-5 lungs per 
group). (E) Quantitation showed no difference in blood vessel density across any of the groups 
(detailed in C). Bar charts,  means ± s.e.m. (n=3-5 tumor burdened lungs analyzed per group). 
(F) Transwell cell invasion assay showed no significant difference in invasion between B16F0 
cells treated with conditioned medium from either WT pericytes or 3-null pericytes (n=9-11 
technical repeats). (G) E0771 cells were co-injected with WT- or 3-null pericytes into the 
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mammary fat pad of C75BL/6 mice.  Mice were culled when tumors reached 600 mm3 and lung 
metastases assessed (n= 8-9 mice/group). Representative images of H&E stained sections are 
given. (H) Conditioned medium from WT or 3-null pericytes was applied to B16F0, B16F10 
and LLC cells and cell survival measured by MTS assays. Results are means ± s.e.m. relative 
to tumor cells treated with conditioned media from WT pericytes (n= 3 experimental repeats). 
*p < 0.05, **p < 0.01, ***p < 0.001. N.S., no significant difference. PC, pericytes. (A) Two-way 
ANOVA test. (B-H) Student’s t test. Scale bars in (B, G) 50 µm, (C) gross lung, 1.0 cm, and 
H&E sections, 100 µm, (D) 500 µm, (G) 50 µm. 
 
Figure 5, Loss of pericyte-3-integrin expression significantly increases FAK-pHGFR-
pAkt-p-p65 dependent cytokine production. (A) Volcano plots of phosphoproteomic analysis 
shows significant enhancement of several phosphoproteins including FAK in 3-null vs WT 
pericytes.  (B) Analysis of receptor tyrosine kinase (RTK) arrays or tyrosine kinase (TK) arrays 
shows a significant increase in p-HGFR, p-Akt (S473) and p-Akt (T308) levels in 3-null 
pericytes compared with WT pericytes (n= 4 dots from 2 experimental repeats). (C) Western 
blot analysis of WT and 3-null pericyte lysates. Bar charts represent densitometric values ± 
s.e.m (n=3 experimental repeats). Hsc70, loading control. (D) Protein-profiler cytokine array 
analysis of fold increase in cytokine expression between WT and 3-null pericytes (n=4 dots 
from 2 experimental repeats). Representative images of the relevant dots from the cytokine 
arrays are given. Human cutaneous melanoma, lymphoma and ER+ breast cancer samples 
were double immunostained for the mural cell marker -SMA and for either p-Akt (E) or nuclear 
p65 (F). High proportions of mural-3-integrin negative blood vessels is associated with 
elevated levels of p-Akt and nuclear p65 in all human cancers (n=5-6 patient samples). 
Representative images of double immunostained sections from each cancer type for -SMA 
and with either p-Akt or p65 are given. Arrows highlight p-Akt (E) or nuclear p65 (F) staining. 
Each sample in the violin plots given represents individual tumors from separate patients. 
Means ± S.E.M are given. (G) Western blot analysis of 3-null pericytes after treatment with 
vehicle alone (DMSO) or FAK inhibitor (PF573228 10 M). Blots are representative of 3 
separate experiments. 3-null pericytes were treated with either vehicle alone (DMSO), HGFR-
inhibitor (H) or Akt-inhibitor (I) for 10, 30 and 60 minutes. Western blot analysis of DMSO, 
HGFR-inhibitor or Akt-inhibitor treated 3-null pericytes. Bar charts represent means ± s.e.m. 
(n=3 experimental repeats). *p < 0.05, **p <0.01, ***p <0.001. (B-I) Student’s t test. Scale bars 
in (E, F) 10 µm. 
 
 
Figure 6, Deletion of pericyte-3-integrin enhances tumor cell growth via pericyte-pAkt-
p65 regulated cytokine production. (A) Western blot analysis of 3-null pericytes with 
CRISPR-Cas9 deletion of Akt1 (3-null;AktKO PC) or HGFR (3-null;HGFRKO PC) compared 
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with 3-null;Cas9 controls. Hsc70, loading control. Blots representative of 3 separate 
experiments. (B) B16F0 cell survival after exposure to conditioned media from 3-null;AktKO , 
3-null;HGFRKO, or 3-null;Cas9 pericytes (n= 16 technical replicates for 2 separate 
experiments). (C) Tumor growth in WT mice injected subcutaneously with either B16F0 cells 
plus 3-null;Cas9 pericytes or B16F0 plus 3-null;AktKO pericytes at 1:8 ratio. (D) Western blot 
analysis using mock- and I-B-SR-transfected WT or 3-null pericyte lysates. HSC70, loading 
control. (E) Protein-profiler cytokine arrays. Quantitation of fold difference in cytokine 
expression between mock- and I-B-SR-transfected 3-null pericytes (n=4 dots from 2 
independent experiments). (F) Conditioned media from mock- and I-B-SR-transfected 3-
null pericytes were applied to B16F0, B16F10 and LLC cells and cell survival measured by 
MTS assay. Bar charts, means ± s.e.m. relative to tumor cells treated with conditioned media 
from mock-transfected 3-null pericytes (n=3 experimental repeats). (G) Wild type mice were 
injected via the tail vein with either B16F10 cells and mock-transfected 3-null pericytes or 
B16F10 cells and I-B-SR-transfected 3-null pericytes and lungs harvested for lung nodule 
analysis at 21 days post injection with representative gross lung and H&E stained  sections 
(n=3 mice/group). Bar charts, means ± s.e.m. for numbers of lung nodules and sizes of lung 
nodules across all groups. (H) Western blot confirmed the CRISPR-Cas9 depletion of CXCL1, 
CCL2 or TIMP-1 in 3-null pericytes back to WT;Cas9 levels. Bar charts, densitometric analysis. 
(I) MTS cell survival of B16F0 cells exposed to conditioned medium from Cas9-control 
transfected3-null pericytes (3-null;Cas9), or CRISPR-knockout CXCL1, TIMP-1 or CCL2 3-
null pericytes (namely, 3-null;CXCL1KO, 3-null;TIMP-1KO, 3-null;CCL2KO respectively). 
Results are means ± s.e.m. relative to tumor cells treated with conditioned media from 3-
null;Cas9. (J) Tumour growth in WT mice injected subcutaneously with either B16F0 cells plus 
3-null;Cas9 pericytes, or B16F0 plus 3-null;CXCL1KO, 3-null;TIMP-1KO , or 3-null;CCL2KO 
pericytes. Bar charts, means ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001. N.S., no significant 
difference. (B, E-G, I) Student’s t test. (C, J) Two-way ANOVA test. Scale bar in (G) gross lung, 
1.0 cm, and H&E sections, 100 µm 
 
Figure 7, Deletion of pericyte-3-integrin increases tumor cell growth via pericyte-CCL2 
and tumor cell-MEK1 and ROCK2 pathways.  
(A) KSEA analysis of phosphoproteomics identifies kinase substrate pathway enrichment in 
B16F0 cells exposed to conditioned medium from 3-null pericytes compared with B16F0 cells 
exposed to conditioned medium from WT pericytes. (B) Phospho-MLC2 immunohistochemical 
staining, and signal intensity maps. Bar chart, H-score of mean signal intensity ± s.e.m. in 
B16F0 tumors co-injected with WT or 3-null pericytes.  (C) Western blot analysis in B16F0 
cells exposed to conditioned medium from 3-null;Cas9 or 3-null:CCL2KO pericytes. Blots are 
representative of 3 separate experiments. (D) Phospho-MLC2 staining and intensity maps in 
B16F0 tumors co-injected with WT;Cas9, 3-null;Cas9 or 3-null;CCL2KO pericytes. Bar chart, 
H-score of mean signal intensity ± s.e.m. (E) Western blot analysis of B16F0 cells treated with 
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MEK1 inhibitor U0126 indicating inhibition of the MEK effector ERK1/2, and of p-MLC2 in B16F0 
cells treated with the ROCK2 inhibitor GSK269962A indicating inhibition of activity of the ROCK 
effector MLC2. (F) B16F0 cells were exposed to conditioned medium from WT or 3-null 
pericytes in combination with either vehicle, MEK1 inhibitor, U0126 or ROCK2 inhibitor, 
GSK269962A and B16F0 cell survival measured in MTS assay. (G) B16F0;ROCK2KO and 
B16F0;ROCK2WT cells were injected subcutaneously into pdgfrcre-;3fl/fl and pdgfrcre+;3fl/fl 
mice. Once tumors were established, mice were treated with doxycycline to induce ROCK2 
deletion in B16F0 cells in vivo (n= 5-9 mice per group).  Line graph, tumor growth, bar chart, 
mean end tumor volume ± s.e.m.  *p < 0.05, ***p < 0.001. N.S., no significant difference. (B, D, 









KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 





























Rabbit polyclonal anti-NG2 Merck-Millipore CAT#AB5320;RRID:
AB_11213678 






























































Rabbit polyclonal anti-NG2, Alex Fluor®488 conjugated Merck-Millipore CAT#AB5320A4;RRI
D:AB_11203143 
Rat monoclonal PE anti-mouse CD31 BioLegend CAT#102408;RRID:
AB_312903 
Rat monoclonal PE anti-mouse/human CD11b (Mac1) BioLegend CAT#101208;RRID:
AB_312791 
Rat monoclonal APC-anti-mouse CD140b (PDGFR) BioLegend CAT#136008;RRID:
AB_2268091 
Rat monoclonal APC-anti-mouse CD140a (PDGFR) BioLegend CAT#135908;RRID: 
AB_2043970 
Rat monoclonal PE/Cy7-anti-mouse CD146 BioLegend CAT#134714;RRID:
AB_2563109 
Rabbit polyclonal anti-collagen IV Abcam CAT#ab6586;RRID:
AB_305584 





Rabbit monoclonal anti-3-integrin Abcam CAT#ab75872;RRID
:AB_2249317 




Rat monoclonal anti-mouse FCsort-RII/III BD Biosciences  CAT#553141;RRID:
AB_394656 
Rat monoclonal anti-mouse ICAM-2 BD Biosciences CAT#553326;RRID:
394784 
Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed 





Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed 






Donkey anti-Rat IgG (H+L) Highly Cross-Adsorbed 






Biotinylated goat anti-rabbit secondary antibody Vector Laboratories CAT#BA-
1000;RRID:AB_2313
606 
Bacterial and Virus Strains 
N/A N/A N/A 
Biological Samples   
Human ER+ breast cancer samples Barts Cancer Institute 





Human melanoma, mesothelioma and diffuse large B-
cell lymphoma 
Barts Cancer Institute 
tissue Bank 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
ProlongTM Gold Anti-Fade Mountant with DAPI ThermoFisher 
Scientific  
CAT#P36931 
Dual Endogenous Enzyme-Blocking Reagent Dako CAT#S2003 
Citric acid based antigen unmasking solution Vector Laboratories CAT#H-
3300;RRIDAB_2336
226 




Vector® VIP Peroxidase (HRP) Substrate Kit Vector Laboratories CAT#SK-
4600;RRID:AB_2336
848 
OCT Killik, Bio-Optica, IT CAT#W01030799 
Hoechst dye Sigma-Aldrich CAT#B2261 
Collagenase type I Gibco CAT#17100017 
Gelatin Sigma-Aldrich CAT#G9136 
Fibronectin Merck-Millipore CAT#FC010 
DYNAL® sheep anti-rat IgG-conjugated magnetic beads ThermoFisher 
Scientific 
CAT#11035 
CellTrackerTM Red CMTPX Dye ThermoFisher 
Scientific 
CAT#C34552 
Lipofectamine 2000 ThermoFisher 
Scientific 
CAT#11668019 
MegaMix-Blue MicroZone, Client life 
science 
CAT#2MMB-100 
HGFR inhibitor (PHA-665752) Merck CAT#PZ0147-25MG 
Akt inhibitor (LY294002) Merck CAT#L9908 
FAK inhibitor (PF573228) TORCIS CAT#3239 
ROCK inhibitor (GSK269962A) TORCIS CAT#4009 
MEK inhibitor (U0126) TORCIS CAT#1144 




Critical Commercial Assays 
HypoxyprobeTM-1 Kit Hypoxyprobe, Inc CAT#HP1-1000Kit 
Tyramide SuperBoost™ Kit ThermoFisher 
Scientific 
CAT#B40953 
Vevo MicromarkerTM Contrast Agent Kit Visualsonics N/A 
CellTiter 96® Aqueous One Solution Reagent Promega CAT#G3582 
Proteome-Profiler Mouse Cytokine Array Kit R&D systems CAT#ARY006 
Proteome Profiler Phospho-Receptor Tyrosine Kinase 
Array Kit 
R&D systems CAT#ARY001B 
Proteome Profiler Tyrosine Kinase Array Kit R&D systems CAT#ARY003B 
Deposited Data 
Mass spectrometry proteomics data the ProteomeXchange 
Consortium 
PXD014513 
Experimental Models: Cell Lines 
LLC ATCC CRL-1642 
B16F0 ATCC CRL-6322 
B16F10 ATCC CRL-6475 
E0771 CH3 Biosystems SKU:940001 
Experimental Models: Organisms/Strains 
Mouse: pdgfrcre  Foo et al., 2006 N/A 
Mouse: 3fl/fl Morgan et al., 2010 N/A 
Mouse: pdgfrcre-;3fl/fl This paper N/A 
Mouse: pdgfrcre+;3fl/fl This paper N/A 
Mouse: mTmG Cancer Research UK N/A 
Mouse: pdgfrcre-;mTmG This paper N/A 
 
Mouse: pdgfrcre+;mTmG This paper N/A 
Mouse: RIPtag-2 Hanahan, 1985  N/A 
Mouse: RIPtag-2;pdgfrcre-;3fl/fl This paper N/A 
Mouse: RIPtag-2;pdgfrcre+;3fl/fl This paper N/A 
Oligonucleotides 
PCR primers, see method This paper N/A 
shRNA sequences for ROCK2 and non-targeting 
shControl, see method 
This paper GenScript USA Inc. 
sgRNAs sequences for TIMP-1, CXCL1, CCL2, Akt1 
and HGFR, see table S1 
This paper Invitrogen 
Recombinant DNA 
Lenti-CRISPR–EGFP plasmid Addgene CAT#75159 
pLKO-neo lentiviral shRNA construct Addgene CAT#21916 
pMDLg/pRRE Addgene CAT#12251 
pRSV-Rev Addgene CAT#12253 
pMD2.G Addgene CAT#12259 
Software and Algorithms 
ImageJ Schneider et al., 2012 https://imagej.nih.go
v/ij/ 
Graphpad Prism (Version 6 and 8) Graphpad http://graphpad.com 
Flowjo N/A https://www.flowjo.co
m 
QuPath v0.1.2 Quantitative Pathology 
& Bioimage analysis 
https://qupath.github.
io/ 






CRISPOR algorithm Cripsor http://crispor.tefor.ne
t 
Pescal software Wilkes et al., 2017 N/A 
Mascot Daemon 2.5.0 Mascot N/A 
VevoCQTM
 
contrast quantification software Visualsonics N/A 
Other 
Nucleofector® electroporation system Lonza Nucleofactor® II 
Neon Transfection system  ThermoFisher 
Scientific 
MPK5000 
NanoZoomer S210 slide scanner Hamamatsu, Japan S210 
FACSAriaTM III flow cytometer BD Biosciences FACSAriaTM III 
Nano SPECT/CT® In vivo preclinical imager BioScan Nano SPECT/CT®  
Ultrasound imaging system Visualsonics Vevo® 2100 system 
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Wong, Muñoz-Félix et al.,  Figure 2
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H&E
Wong, Muñoz-Félix et al.,  Figure 4
Endomucin
α-SMA
Figure4 Click here to access/download;Figure;Figure 4_Wong et al.,
19-11-2019.pdf
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Figure6 Click here to access/download;Figure;Figure 6_Wong et al. 09-
01-2020.pdf
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ROCK2 ** Rdx(T564) Msn(T558) Ezr(T567) Myl12b(S20) 
MEK1 *** Mapk1(Y185) Mapk1(T183) Mapk3(Y205) Mapk3(T203) 
DAPK1 ** Myl12b(T19) Myl12b(S20) 
DAPK3 ** Myl9(T19) Myl9(S20) 
smMLCK ** Myl9(T19) Myl9(S20) 
PKCE * Prkd1(S748) Stat3(S727) 
PKACA *
Vim(S39) Vim(S7) Mapt(S506) Vim(S51) Arhgef2(S885) 
Stmn1(S63) Marcks(S163) Marcks(S156) Bad(S136) Ywhah(S59) 
Crem(S133) Marcks(S152) Bad(S155) Marcks(S160) Stmn1(S16) 
Lck * Mapk1(Y185) 
AurB * Vim(S39) Vim(S7) 
CDK5 * Axin1(T480) Cdkn1b(S10) Stat3(S727) Stmn1(S38) 
GSK3B *
Axin1(S485) Axin1(T480) Dpysl2(T514)  Map1b(S1260) 
Zbed3(S111) Rcan1(S112) Rcan1(S108) Myc(T58) Dpysl2(T509) 
Pax3(S201) Ctnnd1(S252) 


















































































































































































   
   







Figure7 Click here to access/download;Figure;Figure 7_Wong et al.,
09-01-2020.pdf
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Wong, Muñoz-Félix et al.,  Supplementary Figure 1
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Wong, Muñoz-Félix et al.,  Supplementary Figure 3





















































































































































































































































































































































































































































































































































































































































































































































































































B16F10:WT PC   
1:8
B16F10:β3-null PC
Endomucin α-SMA Merge Endomucin α-SMA Merge
Wong, Muñoz-Félix et al.,  Supplementary figure 4 
related to figure 4
Wong, Muñoz-Félix et al., Supplementary Figure 5



































































































































































































































































































































































Wong, Muñoz-Félix et al.,  Supplementary Figure 6
related to Figure 6 and 7
D
A
Map2k2(S222) *** Dual specificity mitogen-activated protein kinase kinase 2 
Myl12b(S20) *** Myosin regulatory light polypeptide 9 
Ezr(T567) *** Ezrin
Stat3(S727) *** Signal transducer and activator of transcription 3 
Cdk7(T170) ** Cyclin-dependent kinase 7 
Vim(S39) ** Vimentin 
Akt3(T309) * RAC-alpha serine/threonine-protein kinase 
Akt1(Y315) * RAC-alpha serine/threonine-protein kinase 
Myl12b(T19) *** Myosin regulatory light polypeptide 9 
Pdcd4(S457) * Programmed cell death protein 4 
Ripk2(S176) ** Receptor-interacting serine/threonine-protein kinase 2
Sphk1(S225) ** Sphingosine kinase 1 
Anxa2(S12) * Annexin A2 
Ran(S135) *** GTP-binding nuclear protein Ran 
Vim(S7) ** Vimentin 
Abl1(S618) *** Tyrosine-protein kinase ABL1
Mtmr2(S58) *** Myotubularin-related protein 2 
Jund(T239) *** Transcription factor jun-D 
Eef1d(S133) ** Elongation factor 1-delta 
Akt1(Y474) * RAC-alpha serine/threonine-protein kinase 
Araf(S257) * Serine/threonine-protein kinase A-Raf 
Hnrnpk(Y380) *** Heterogeneous nuclear ribonucleoprotein K 
Stmn1(S16) ** Stathmin 
Smarcad1(S81) *
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin 
subfamily A containing DEAD/H box 1 
Cdk16(S119) * Cyclin-dependent kinase 17 
Add3(S693) * Alpha-adducin 






















































































































Code% Gene% Target'sequence' Enrichment% Backbone%
CGM48% mTIMP1' GAAACTCTTCACTGCGGTTC' FACS'(EGFP)' PM1326,'pLentiACRISPRA
EGFP'(Addgene'75159)'
CGM50% mCXCL1' ACTTCGGTTTGGGTGCAGTG' FACS'(EGFP)' PM1326,'pLentiACRISPRA
EGFP'(Addgene'75159)'
CGM52% mCCL2' GATGATCCCAATGAGTAGGC' FACS'(EGFP)' PM1326,'pLentiACRISPRA
EGFP'(Addgene'75159)'
CGM66% mAkt1' CATTGAGCGCACCTTCCATG' FACS'(EGFP)' PM1326,'pLentiACRISPRA
EGFP'(Addgene'75159)'
CGM74% mHGFR' ATTCAAGACCGGGCCCGTGT' FACS'(EGFP)' PM1326,'pLentiACRISPRA
EGFP'(Addgene'75159)'
CGM74% mHGFR' ATTCAAGACCGGGCCCGTGT' FACS'(EGFP)' PM1326,'pLentiACRISPRA
EGFP'(Addgene'75159)'
 





Supplementary,Figure,1,,related,to,main,Figure,1., , , Representative,images,of,mural,β34integrin,







Supplementary,Figure,2,,related,to,main,Figure,2., , , , Characterization,of,pdgfrβcre89β3fl/fl,and,
pdgfrβcre+9β3fl/fl,mice,(A)!Crossing!pdgfrβcre()β3fl/fl-and-pdgfrβcre+)β3fl/fl-mice!produced!litters!in!which!







old! pdgfrβcre()β3fl/fl-and- pdgfrβcre+)β3fl/fl-mice.! No! gross! morphological! defects! were! observed.! (F)!
Upper- panels,! Unchallenged! adult! skin! from! pdgfrβcre(\TdTom! immunostained! for! endomucin! and!
PDGFRβ  shows!weak!PDGFRβ expression!in!mural!cells!in!76.6%!dermal!vessels. No!TdTom!signal!
was! observed! in! pdgfrβcre(\TdTom- skin- (data- not- shown).! Unchallenged! adult! skin! from!
pdgfrβcre+\TdTom! shows!TdTom! reporter!signal! in!only!32.6%!of!dermal!blood!vessels.!Left!panel,!
Arrows,! PDGFRβ−positive! vessels,! Arrowheads,- PDGFRβ7negative! vessels.!   Right- panel,- Arrows,-
TdTom7positive! vessels,! Arrowheads! TdTom7negative! vessels.- Lower- panels,! pdgfrβcre(! and!
pdgfrβcre+! mice! were! bred! with! mTmG! reporter! mice,! producing! both- pdgfrβcre()mTmG! and!
pdgfrβcre+)mTmG!mice.!B16F0s!were!subcutaneously!inoculated!into!mice.!Tumor!blood!vessels!were!









pericytes! isolated! from!pdgfrβcre()β3fl/fl-mice-expressed!β37integrin!whereas! pericytes! isolated! from!
pdgfrβcre+)β3fl/fl- mice! did! not.- Both! genotypes! expressed! equal! levels! of! β17integrin, β57integrin,!
PDGFRβ!and!NG2.!Hsc70!acted!as!a!loading!control.!Densitometric!values!are!given!(n=3!experimental!
repeats).! (J)! Endothelial! cells! isolated! from! pdgfrβcre()β3fl/fl- and- pdgfrβcre+)β3fl/fl-mice- showed! no!
deletion!in!β37integrin,!and!expressed!the!endothelial!marker!endomucin!but!not!the!pericyte!marker!







positive! pericytes! (yellow! signal)! on! pdgfrβcre()β3fl/fl- tumor! blood! vessels,! but! β37integrin7negative!
pericytes!on!pdgfrβcre+)β3fl/fl! tumor! blood! vessels.!Bar! chart! represents!mean!pixel! intensity! of!β37
integrin! expression! in!α7SMA! positive! cells! ±! s.e.m! (n=5! tumors! analyzed! per! genotype).! (M)! Ki67!
endomucin!double! staining!and!Ki67!positive! cell! analysis! in! the!perivascular! areas! (dotted- line)! of!












Supplementary, Figure, 3,, related, to, main, Figure, 3., , , Tumor, blood, vessel, density,, pericyte,
coverage, and, leakiness, is, not, affected, by, pericyte4β34integrin4deletion.! Sections! of:! (A)! LLC!
subcutaneous,! (B)!B16F10! lung!nodules,! (C)!LLC! lung!nodule!and! (D)!E0771!orthotopic!mammary!
tumors!were!stained!for!endomucin,!and!the!number!of!vessels!per!mm2!counted.!Quantitation!shows!






Bar! charts! indicate! that! percentage! of! PE7PECAMab! perfused! endomucin7positive! vessels.! (G)!
Sections!of!E0771!orthotopic!mammary!tumors!were!double!immunostained!for!endomucin!and!α7SMA!
and! the! percentage! of! vessels! with! associated! pericytes! counted.! Quantitation! shows! that! the!
percentage!of!α7SMA7positive!tumor!blood!vessels!was!not!affected! in!pdgfrβcre+)β3fl/fl-mice.!(n=779!
subcutaneous!tumors!analyzed!per!group).!(H)!Sections!from!subcutaneous!LLC!tumors!were!double!
immunostained! for! basement!membrane!marker! collagen! IV! (green)! and!CD31! as! an! endothelium!
marker!(red).!Bar!charts!indicate!that!the!percentage!of!blood!vessels!with!collagen!IV!expression!in!
LLC! tumor! vascular! basement! membranes! was! unchanged! between! genotypes! (n=9710! tumors!
analyzed!per!group).!(I)!Relative!area!of!perivascular!Hoechst!dye!leakage!(blue):!PE7PECAM!ab!(red)!






pimonidazole! to! detect! hypoxia.! Bar! charts! represent!means! ±! s.e.m.! (n=475! tumors! analyzed! per!
group).! (K)! Unchallenged! skin! from, pdgfrβcre()β3fl/fl! and! pdgfrβcre+)β3fl/fl-mice! were! sectioned! and!








the! tail!vein.! (C)! ! Immunofluorescence! images!of!endomucin!and!α7SMA!double! immunostaining! in!
sections!of!the!lung!nodules!described!in!main!Figure!4C.!Quantitation!shows!no!difference!in!blood!







alternative, signalling, pathways.! (A)! Phosphoproteomic! analysis! identified! levels! of! FAK1! and!
phosphorylated! Akt1! (Ser122)! and! Akt1! (Ser129)! in!WT! and! β37integrin! null! pericytes.! Bar! charts!
represent!ppm!units!of!3!different!samples!per!group.!(B)!WT!and!β37null!pericytes!were!immunostained!
for!p7p65!and!DAPI.!Quantitation! revealed! that!nuclear!p7p65!was!enhanced!significantly! in!β37null!
pericytes.!Bar!charts!represent!means!±!s.e.m.!(n=3!experimental!repeats).!(C)!Western!blot!analysis!
of! p7HGFR! (Tyr1234/1235),! HGFR,! p7Akt! (S473),! total! Akt,! p7p65! (S536)! and! total! p65! from! WT!
pericytes! treated! with! either! placebo! or! the! β37integrin! inhibitor,! cilengitide.! Bar! charts! represent!
densitometric!values!±!s.e.m!(n=3!experimental!repeats).!Hsc70!acts!as!a!loading!control.!(D,,E)!Triple!













ROCK2,! p7MLC2,!MLC2! and! Hsc70! used! as! loading! control.! (F)! MTS! assay! shows! no! significant!
difference!in!cell!survival!between!B16F0\ROCKWT!and!B16F0\ROCKKO!cells.!*p!<!0.05,!**p!<!0.01,!***p!
<!0.001.!N.S.!No!significant!difference.!(A,,B,,C,and,F)!Student’s!t!test.! !
 
